Ftse Mib
36.200,72
0,24%
DAX
21.394,93
-0,11%
S&P 500
6.101,24
-0,29%
NASDAQ
19.954,30
-0,50%
Bitcoin
104.960,19
0,10%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Ultragenyx Pharmaceutical Inc (RARE) Ultragenyx Pharmaceutical Inc (RARE) Notizie

Ultragenyx Pharmaceutical Inc

RARE
44,05
-0,80 (-1,78%)
25 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/1/202522:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
13/1/202514:30EDGAR2Form 8-K - Current report
12/1/202517:00GLOBEUltragenyx Reports Preliminary 2024 Revenue, Financial..
06/1/202522:30GLOBEUltragenyx to Present at the 43rd Annual J.P. Morgan..
20/12/202422:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
19/12/202422:17EDGAR2Form 8-K - Current report
19/12/202422:05GLOBEUltragenyx Announces First Patient Dosed in Pivotal Phase 3..
19/12/202414:30EDGAR2Form 8-K - Current report
19/12/202414:00GLOBEUltragenyx Submits Biologics License Application to the U.S...
12/12/202400:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/11/202422:30GLOBEUltragenyx to Participate in Investor Conferences in..
20/11/202422:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
12/11/202412:03EDGAR2Form 8-K - Current report
09/11/202416:30GLOBEUltragenyx Presents Positive Update on GTX-102 Angelman..
05/11/202422:06EDGAR2Form 8-K - Current report
05/11/202422:01GLOBEUltragenyx Reports Third Quarter 2024 Financial Results and..
29/10/202421:05GLOBEUltragenyx to Host Conference Call for Third Quarter 2024..
18/10/202422:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
11/10/202422:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/10/202414:15EDGAR2Form 8-K - Current report
07/10/202414:00GLOBEUltragenyx Receives Breakthrough Therapy Designation for..
03/10/202422:34EDGAR2Form 8-K - Current report
03/10/202422:30GLOBEUltragenyx Provides Update on Stage 1 Cohorts in Pivotal..
26/9/202414:00GLOBEUltragenyx Announces Upcoming Setrusumab (UX143)..
18/9/202423:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
18/9/202419:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202417:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202422:30GLOBEUltragenyx to Participate in Investor Conferences in..
23/8/202413:00BWTactical Resources, a Growing North American Rare Earth..
21/8/202422:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
01/8/202422:07EDGAR2Form 8-K - Current report
01/8/202422:05GLOBEUltragenyx Reports Second Quarter 2024 Financial Results and..
25/7/202422:05GLOBEUltragenyx to Host Conference Call for Second Quarter 2024..
24/7/202414:00GLOBEUltragenyx to Present GTX-102 Angelman Syndrome Program..
19/7/202422:05GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
17/7/202422:06EDGAR2Form 8-K - Current report
17/7/202422:05GLOBEUltragenyx Announces Successful End-of-Phase 2 Meeting with..
12/7/202422:04EDGAR2Form S-8 - Securities to be offered to employees in employee..
20/6/202422:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
20/6/202420:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/6/202420:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/6/202420:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202412:31EDGAR2Form 8-K - Current report
14/6/202423:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/6/202402:49GLOBEUltragenyx Announces Pricing of Public Offering of Common..
13/6/202401:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202423:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/6/202423:10EDGAR2Form 144 - Report of proposed sale of securities
12/6/202422:05GLOBEUltragenyx Announces Proposed Public Offering of Common..
12/6/202422:04EDGAR2Form 8-K - Current report
Apertura: 44,81 Min: 44,03 Max: 45,2692
Chiusura: 44,85

La tua Cronologia

NASDAQ
RARE
Ultragenyx Pharmaceutical
BIT
F14160
Vontobel Financial Produ...
BIT
F28946
Vontobel Financial Produ...
BIT
F17890
Vontobel Financial Produ...
BIT
XB34
ETF
BIT
NXT
Next Geosolutions Europe
TG
1RH
Recruit
BIT
BSRID
Exchange Traded
BIT
Q00576
Leonteq Securities
BIT
S28230
Societe Generale Effekten
BIT
EEMK
Exchange Traded
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network